Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Abstract

The value of a multidisciplinary approach to the management of prostate cancer (PC) is widely appreciated by both health care professionals and patients alike. Whether for the navigation of localised PC where management options can be perplexing, or the management of advanced prostate cancer where therapy options are evolving rapidly, and clinical trial options abound, it is best practice that patients are offered multidisciplinary options[1]. This may include the presence of health care practitioners of various types in a physical multidisciplinary clinic, or having a virtual network whereby patients can access multidisciplinary care in different environments. Importantly, a well-run multidisciplinary team (MDT) meeting is the key to anchoring such care and considering all multidisciplinary options for prostate cancer patients. Indeed, this approach is mandated by law in the UK where multidisciplinary care was enshrined in the Health Care Act based on the Improving Outcome Guidance work which underpins cancer care in the National Health Service in the UK. This article is protected by copyright. All rights reserved.